TABLE 4.

Log₁₀ CFU counts at the end of treatment and proportions of relapsed mice 12 weeks after treatment^a

Regimenb	Log10 CFU/lung (mean ± SD; n = 5)						Proportion (%) of mice with relapse after treatment (n = 15)
	Initial	4 wks	8 wks	10 wks	12 wks	14 wks	10 wks	12 wks	14 wks
None	6.190 ± 0.238	NT	NT	NT	NT	NT	NT	NT	NT
Vehicle	NT	6.348 ± 0.303	7.052 ± 0.595	6.667 ± 0.554	5.504 ± 0.193c	6.337 ± 0.629	NT	NT	NT
RHZE/RHd	NT	3.701 ± 0.243	0.947 ± 0.108c	0.685 ± 0.443	0.134 ± 0.084e	0.396 ± 0.445c	12 of 15 (80)	4 of 14 (29)c	1 of 14 (7)c
DCMB	NT	1.706 ± 0.414e	0.000 ± 0.000	0.038 ± 0.034e	0.086 ± 0.099e	0.044 ± 0.098e	0 of 15 (0)	0 of 14 (0)c	0 of 15 (0)

^aICR female mice were intratracheally infected with M. tuberculosis Kurono, and chemotherapy was initiated 14 days after infection for 4, 8, 10, 12, or 14 weeks at 5 days per week. Relapse was defined as a positive lung culture 12 weeks after the end of treatment for the indicated periods. NT, not tested.

^bB, BDQ (25 mg/kg); C, OPC-167832 (2.5 mg/kg); D, DMD (2.5 mg/kg); E, EMB (100 mg/kg); H, INH (25 mg/kg); M, MXF (100 mg/kg); R, RIF (5 mg/kg); Z, PZA (150 mg/kg).

^cOne animal of each group died due to a mistake in administration.

^dZ and E were administered only for the initial 8 weeks.

^eMeans and SD were calculated using the individual-mouse data. For mice with one or more contaminated plates but with the rest of the plates containing no M. tuberculosis, we used a detection limit methodology, as described in Materials and Methods. For detailed calculations of mouse data using this methodology, see Table S6 in the supplemental material.